24.10.2011 • NewsABBStatoilAker Solutions

ABB to Power Subsea Oil and Gas Field in Norwegian Sea

ABB said it has won an order worth about $36 million from oil services company Aker Solutions to provide drives and transformers to their subsea power distribution system for the Asgard subsea oil and gas field operated by Norway's Statoil. The order was booked in the third quarter.

ABB's equipment will ensure power as well as optimized motor speed and control, for the world's first subsea gas compression system from onboard the Asgard A floating vessel off the northern coast of Norway. The electrical system will be able to transmit 15 megavolt-amperes and 189 hertz, enough to power over 10,000 homes, over a distance of 43 kilometers. Once completed, this will be a world record distance as well as the highest voltage and frequency achieved between a drive on a floating production facility and a compressor on the seabed.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.